Clinical Study

Acacia Senegal (Gum Arabic) Supplementation Modulate Lipid Profile and Ameliorated Dyslipidemia among Sickle Cell Anemia Patients

Lamis Kaddam,1 Imad Fadl-Elmula,2 Omer Ali Eisawi,3 Haydar Awad Abdelrazig,4 and Amal M. Saeed5

1Department of Physiology, Faculty of Medicine, Neelain University, Khartoum, Sudan
2Neelain Research Centre, Faculty of Medicine, Neelain University, Khartoum, Sudan
3Department of Hematology, Military Hospital, Khartoum, Sudan
4Department of Pediatrics, Military Hospital, Khartoum, Sudan
5Department of Physiology, Faculty of Medicine, University of Khartoum, Khartoum, Sudan

Correspondence should be addressed to Lamis Kaddam; lamiskaddam@hotmail.com

Received 25 March 2019; Revised 18 May 2019; Accepted 2 June 2019; Published 18 June 2019

Academic Editor: Maurizio Averna

Copyright © 2019 Lamis Kaddam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Sickle cell disease (SCD) is an inherited haemolytic anemia with a variable course and severity. Knowledge of prognostic biomarkers may help in the establishment of therapeutic intervention, management, and follow-up of patients. There have been scattered reports of low high-density lipoprotein cholesterol (HDL-C) and increased triglyceride (TG) in SCD patients. In addition, TG levels have been suggested to be elevated in patients with increased endothelial activation. An increased TG level has been associated with haemolysis, vascular dysfunction, and increased prevalence of pulmonary hypertension. Gum Arabic (GA) is an edible, dried, gummy exudate from the acacia Senegal tree. Several studies on GA ingestion have shown reduced plasma cholesterol and low-density lipoprotein (LDL) concentrations in both animals and humans. We investigated GAs therapeutic potential to modulate serum lipids in patients with sickle cell anemia.

Methods. This study recruited and documented secondary outcomes in 47 patients (aged 5–42 years) carrying hemoglobin SS. The patients received 30 g/day of GA for 12 weeks. Total cholesterol, TG, LDL, and HDL were measured before and after GA intake. Cobas C311 (Roche, Germany) automated chemistry analyser was used for direct determination of the values of the lipid profile. Results. GA significantly decreased total cholesterol (TC), TG, and LDL (p = 0.006, 0.04, and 0.02, resp.). GA showed no effect on HDL level. Baseline serum TG and LDL correlated significantly with the hydrogen peroxide ($H_2O_2$) level, which is known as an oxidative stress marker (p = 0.003 and 0.04, resp.). None of the lipid profile elements correlated with age. Conclusion. Our results revealed that dyslipidemia in sickle cell patients is associated with oxidative stress but not associated with age. The findings showed that GA significantly decreased TC, LDL, and TG levels, revealing a novel effect of GA, which is considered a natural dietary fibre that can modulate lipid profile in patients with sickle cell anemia. Trial Registration. This retrospective trial is registered with ClinicalTrials.gov Identifier: NCT02467257 on 3 June, 2015.

1. Introduction

Sickle cell disease (SCD) is a haemoglobinopathy characterised by red cell rigidity, compromised perfusion, and tissue infarction [1]. Previous studies assumed that SCD patients may develop characteristics of metabolic syndrome, presenting with hyperglycemia, hypertension, and dyslipidemia [1, 2]. Reactive oxygen species lead to defects in plasma and erythrocyte lipids [3]; therefore, oxidative stress not only is linked to chronic inflammation, but also contributes to endothelial dysfunction [4]. These two morbid processes disturb lipid homeostasis, which, in turn, may lead to atherosclerosis in SCD patients [5]. Abnormal lipid homeostasis may have the potential to alter the membrane fluidity and functions of red blood cells in individuals with SCD [6]. Lipid profile (triglyceride [TG], total cholesterol
| Characteristics             | Mean   | SD     | Median | Maximum | Minimum |
|----------------------------|--------|--------|--------|---------|---------|
| Age                        | 16.26  | 8.52   | 15     | 42      | 5       |
| Gender                     | 23(49%) Male                        |
| Baseline BMI               | 15.51  | 14.65  | 24.9   | 63      | 9.8     |
| S. Cholesterol (mg/dL)     | 109.9  | 23.39  | 107    | 164     | 70      |
| S.TSG (mg/dL)              | 126.6  | 48.96  | 116    | 301     | 62      |
| S. LDL mg/dL               | 64.2   | 22.12  | 59     | 124     | 27      |
| S.HDL mg/dL                | 31.36  | 10.79  | 30     | 56      | 11      |

**Table 2: Comparison between the mean of pre- and postintervention values of lipid profile and H$_2$O$_2$.**

| Biomarker                     | Baseline mean ±SD | Postintervention mean ±SD | PV.  | 95% confidence interval |
|-------------------------------|-------------------|---------------------------|------|-------------------------|
| S. Cholesterol (mg/dL)        | 109.9±24          | 102.1±22                  | .006** | 2.353-13.136           |
| S.TSG (mg/dL)                 | 126.6±49          | 114.1±41.9                | .048* | .1376-25.224            |
| S. LDL mg/dL                  | 64.2±22.12        | 58.9±22.12                | .025* | .6829-9.7852            |
| S.HDL mg/dL                   | 31.36±10.8        | 29.47±10.63               | .097  | -.35852-4.1457          |
| S.H$_2$O$_2$ (mmol/L)        | 0.47±0.21         | 0.36±0.16                 | .004** | .03798-18.202          |

* Difference is significant at the 0.05 level (2-tailed).
** Difference is significant at the 0.01 level (2-tailed).

[TC], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) is considered a reliable assessment of coronary artery disease risk factors [7, 8]. Earlier studies in patients with SCD reported a significant increase in TG levels [9]. They also found decreased levels of TC, HDL-C, and LDL-C [3, 8, 9]. Dyslipidemia is a major concern, since it is linked with increased mortality [1, 6]. Moreover, dyslipidemia among patients with sickle cell anemia poses an uncertain threat for coronary vascular disease and pulmonary hypertension [1, 8, 10] in particular with increase longevity among sickle patients compared to the past [2].

Gum Arabic (GA) is an edible, dried, gummy exudate from the stems and branches of Acacia Senegal and Acacia Senegal. Oral intake of GA has been shown to provide several health benefits [11], such as prebiotic effects. GA is considered an antioxidant and cytoprotective agent [12–14]. Reports on the effects of GA on lipid metabolism in clinical trials and animal experiments are inconsistent [13, 15, 16]. Several studies have reported that GA ingestion reduces plasma cholesterol and LDL concentrations in humans, but the effect is mild [16–18]. Other studies showed no effect of GA on the lipid profile [19, 20].

Earlier we reported the effect of GA as a fetal hemoglobin-inducing agent and potent antioxidant agent among SCA [21, 22]. Our aim in this report is to investigate the effect of GA ingestion on the serum lipid profile among sickle cell patients.

### 2. Patients and Methods

This was a Phase II, single-arm trial carried out for investigating the effect of GA as a lipid-lowering agent among sickle cell patients. Details of entry criteria and recruitment were presented previously [21].

### 3. Gum Arabic Administration

GA in powder form is a 100% natural extract powder produced mechanically from the wildly grown acacia Senegal tree with a particle size less than 210 μm. GA was provided from Dar Savanna Ltd., Khartoum, Sudan. The properties and composition of GA have been listed elsewhere [23]; furthermore, the GA dose and administration were described in detail in a previous report [21].

Blood samples were collected before administering GA and after 12 weeks, with 2 ml in an EDTA container and 2 ml in a plain container. TC, TG, LDL, and HDL were measured before and after GA intake. Cobas C311 (Roche, Germany) automated chemistry analyser was utilized for directly determining the values of the lipid profile. The hydrogen peroxide level was determined calorimetrically using a method developed by Fossati et al. [24].

Data were analysed using SPSS version 20. Paired samples’ t-test was selected for comparing the pre- and postintervention results. Pearson correlation was chosen to find the correlation between different parameters, and p-values ≤ 0.05 were considered significant.

### 4. Results

Forty-seven patients were enrolled. All were Sudanese and aged 5–42 years; 23 were males (Table 1). Oral GA intake significantly decreased the levels of TC, TG, and LDL (Table 2). We observed significant positive correlations between the baseline TC and H$_2$O$_2$ (Figure 1). We also found a significant correlation between TG and H$_2$O$_2$ (Figure 2).
A point mutation in the beta globin gene results in a dysfunctional red blood cell and leads to the vasculopathy that defines SCD [25]. In SCD patients, cholesterol metabolism appears dysfunctional, as evidenced by abnormal plasma cholesterol, TG, and fatty acid content, in addition to low HDL [25, 26]. To date, there is no well-established consensus among providers on the management of the complications of SCD [27]. Many therapeutic strategies have been investigated to decrease the morbidity and mortality associated with SCD. Cholesterol-lowering agents have been found to be beneficial in reducing inflammatory markers among SCD patients [28, 29]. Moreover, previous studies revealed the therapeutic role of GA among SCA patients [21]. GA significantly augmented fetal hemoglobin level and showed potent antioxidant properties that had positive impact on patients’ clinical condition and disease severity [21, 22]. Report’s results revealed advantageous effect of GA on Lipid profile. GA significantly lowered the level of total cholesterol, LDL, and TSG. All of them are risk factors for atherosclerosis and metabolic syndrome [7]. GA did not increase HDL level, which would be favorable for SCD patients. Our results are consistent with previous study conducted among Sudanese population; GA reduced LDL with no effect on HDL [30]. And other contradictory outcomes revealed the augmenting effect of GA on HDL among diabetic patients [31]. Recent study conducted among Sudanese SCA patients showed low HDL among all participants and considered it as risk factor for metabolic syndrome [32]. And similar results were documented from the United States [2]. This could be explained by the pathogenesis of disease itself. Low HDL among sickles could be attributed to the nature of the disease rather than external factors. SCA patients exhibited low level of HDL-bound lecithin cholesterol acyltransferase enzyme (LCAT) and ApoAI- HDL function [22, 26].

The study revealed significant correlation between TC and TSG and H$_2$O$_2$ levels (Figures 1 and 2). H$_2$O$_2$ is considered as toxic molecule to human tissues [33]. Sickle cell erythrocytes produce twice as much superoxide, H$_2$O$_2$, and hydroxyl radical as compared to normal healthy controls [34]. Relation between oxidative stress and dyslipidemia has been studied in different diseases like kidney disease [35] and metabolic syndrome [36, 37]. However, previous study showed negative relationship between oxidative stress and hypocholesterolemia [3]. In this study they measure MDA as oxidative marker instead of H$_2$O$_2$.

GA is soluble dietary fibers with prebiotic properties [38]. Prebiotics are considered as oligo- or polysaccharides fermented by colonic bacteria to produce short chain fatty acids [39]. Prebiotics is recently considered as novel modulator of lipid profile in vivo. Prebiotic ingestion is claimed to modulate fat content and associated metabolic disorders [31, 39–41].

Several limitations should be addressed. The study is single arm since we were aiming to investigate GA efficacy as lipid modulator among SCA patients. The short trial duration withholds us to confirm the clinical significance of our results in terms of atherosclerosis pathogenesis and related mortality. The inference of current trial is GA modulated lipids profile in favorable way among SCA patients, since it decreased LDL level. On the other hand, the most significant decline was recorded on TC level since SCA patients may have normal or low TC level compared to control; GA lowering effect may not be that beneficial to SCA patients. Thus longer and multiarm studies are recommended to affirm our findings and
explore therapeutic outcome of GA on lipid profile among sickles.

6. Conclusion

Our results have shown that dyslipidemia in sickle cell patients is associated with oxidative stress. GA significantly decreased total cholesterol, LDL, and triglycerides levels; findings discovered a novel effect of GA, which might be consumed as natural dietary fiber to modulate lipid profile in patients with SCD and other diseases associated with dyslipidemia.

Abbreviations

GA: Gum Arabic
SCD: Sickle cell disease
SCA: Sickle cell anemia
H2O2: Hydrogen peroxide
HbS: Sickle hemoglobin
TC: Total cholesterol
LDL: Low-density lipoprotein
HDL: High-density lipoprotein
TSG: Triglycerides.

Data Availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval

The study was ethically approved from the Institutional Review Board at Neelain University and from Research Ethics Committee, Khartoum State Ministry of Health.

Consent

Principal investigator obtained informed consent from each participant or from parents or legal guardians when the patient was less than 18 years prior to enrollment to publish the data without breaching confidentiality.

Conflicts of Interest

No conflicts of interest, financial or otherwise, are declared by the authors.

Authors’ Contributions

Lamis Kaddam, Imad Fadl-Elmula, and Amal M. Saeed participated in study design. Lamis Kaddam, Imad Fadl-Elmula, and Amal M. Saeed were involved in all aspects of the study conduct. Lamis Kaddam, Amal M. Saeed, and Imad Fadl-Elmula participated in the writing and review of the manuscript. Lamis Kaddam and Amal M. Saeed analyzed data. Lamis Kaddam performed laboratory studies. Omer Ali Eisawi and Haydar Awad Abdelrazig were significant clinical contributors to the study. All authors approved final version of manuscript.

Acknowledgments

We would like to thank Dar Savanna Ltd., Khartoum, Sudan (http://www.darsavanna.net/), for providing gum Arabic as gift for the study. We also thank the Department of Clinical Chemistry, Central Laboratory Military Hospital, for their valuable help in measuring serum lipid profile. This research was funded by a grant from Sudanese Higher Education and Scientific Research Ministry to Amal M. Saeed. Supporting fund was also obtained from Neelain University, Khartoum, Sudan, to Principal Investigator Lamis Kaddam.

References

[1] S. Zorca, L. Freeman, M. Hildesheim et al., “Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension,” British Journal of Haematology, vol. 149, no. 3, pp. 436–445, 2010.
[2] F. J. Ogunsile, S. M. Bediako, J. Nelson et al., “Metabolic syndrome among adults living with sickle cell disease,” Blood Cells, Molecules, and Diseases, vol. 74, pp. 25–29, 2019.
[3] Y. E. Oztas, S. Sabuncuoglu, S. Unal, H. Ozguenes, and N. Ozguenes, “Hypocholesterolemia is associated negatively with hemolysate lipid peroxidation in sickle cell anemia patients,” Clinical and Experimental Medicine, vol. 11, no. 3, pp. 195–198, 2011.
[4] R. Henneberg, M. F. Otku, A. E. Furman, A. J. Nascimento, and M. S. Leonart, “Protective effect of flavonoids against reactive oxygen species production in sickle cell anemia patients treated with hydroxyurea,” Revista Brasileira de Hematologia e Hemoterapia, vol. 35, no. 1, pp. 52–55, 2013.
[5] S. Voskou, M. Aslan, P. Fanis, M. Phylactides, and M. Kleanthous, “Oxidative stress in β-thalassaemia and sickle cell disease,” Redox Biology, vol. 6, pp. 226–239, 2015.
[6] M. S. Buchowski, L. L. Swift, S. A. Akohoue, S. M. Shankar, P. J. Flakoll, and N. Abumrad, “Defects in postabsorptive plasma homeostasis of fatty acids in sickle cell disease,” Journal of Parenteral and Enteral Nutrition, vol. 31, no. 4, pp. 263–268, 2007.
[7] R. K. Upadhyay, “Emerging risk biomarkers in cardiovascular diseases and disorders,” Journal of Lipids, vol. 2015, Article ID 971453, 50 pages, 2015.
[8] R. K. D. Ephraim, P. Adu, E. Ake et al., “Normal non-HDL cholesterol, low total cholesterol, and HDL cholesterol levels in sickle cell disease patients in the steady state: a case-control study of tena metropolis,” Journal of Lipids, vol. 16, Article ID 7650530, 5 pages, 2016.
[9] M. Pikikidou, M. Yavropoulou, M. Antoniou et al., “Arterial stiffness and peripheral and central blood pressure in patients with sickle cell disease,” The Journal of Clinical Hypertension, vol. 17, no. 9, pp. 726–731, 2015.
[10] M. A. Elsharawy, K. M. Moghazy, and M. A. Shawarby, “Atherosclerosis in sickle cell disease - a review,” International Journal of Angiology, vol. 18, no. 2, pp. 62–66, 2009.
[11] O. Nasir, “Renal and extrarenal effects of gum arabic (Acacia senegal) - what can be learned from animal experiments?”
Kidney and Blood Pressure Research, vol. 37, no. 4-5, pp. 269–279, 2013.

[12] A. A. Ahmed, J. S. Fedail, H. H. Musa, A. A. Kamboh, A. Z. Sifaldin, and T. H. Musa, “Gum Arabic extracts protect against hepatic oxidative stress in alloxan induced diabetes in rats,” Pathophysiology, vol. 22, no. 4, pp. 189–194, 2015.

[13] B. H. Ali, A. Ziada, and G. Blunden, “Biological effects of gum arabic: a review of some recent research,” Food and Chemical Toxicology, vol. 47, no. 1, pp. 1–8, 2009.

[14] B. H. Ali, I. Al-Husseni, S. Beegam et al., “Effect of gum Arabic on oxidative stress and inflammation in adenine-induced chronic renal failure in rats,” PLoS ONE, vol. 8, no. 2, Article ID e55242, 2013.

[15] K. Ushida, H. Hatanaka, R. Inoue, T. Tsukahara, and G. O. Phillips, “Effect of long term ingestion of gum arabic on the adipose tissues of female mice,” Food Hydrocolloids, vol. 25, no. 5, pp. 1344–1349, 2011.

[16] G. Annison, R. P. Trimble, and D. L. Topping, “Feeding Australian Acacia gums and gum arabic leads to non-starch polysaccharide accumulation in the cecum of rats,” Journal of Nutrition, vol. 125, no. 2, pp. 283–292, 1995.

[17] A. H. Ross, M. A. Eastwood, W. G. Brydon, J. R. Anderson, and D. M. Anderson, “A study of the effects of dietary gum arabic in humans,” American Journal of Clinical Nutrition, vol. 37, no. 3, pp. 368–375, 1993.

[18] K. A. Mee and D. L. Gee, “Apple fiber and gum Arabic lowers adipose tissues of female mice,” Journal of Longevity, vol. 9, no. 1, p. 7, 2014.

[19] C. D. Jensen, G. A. Spiller, J. E. Gates, A. F. Miller, and J. H. Whittam, “The effect of acacia gum and a water-soluble dietary fiber mixture on blood lipids in humans,” Journal of the American College of Nutrition, vol. 12, no. 2, pp. 147–154, 1993.

[20] W. L. Haskell, G. A. Spiller, C. D. Jensen, B. K. Ellis, and J. E. Gates, “Role of water-soluble dietary fiber in the management of elevated plasma cholesterol in healthy subjects,” American Journal of Cardiology, vol. 69, no. 5, pp. 433–439, 1992.

[21] L. Kaddam, I. FdleAlmula, O. A. Eisawi et al., “Gum Arabic as a fetal hemoglobin inducing agent in sickle cell anemia; in vivo study,” BMC Hematology, vol. 15, no. 1, p. 19, 2015.

[22] L. Kaddam, I. FdlE-Almula, O. A. Eisawi et al., “Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial,” BMC Hematology, vol. 17, no. 1, p. 4, 2017.

[23] O. Nasir, A. T. Umbach, R. Rexhepaj et al., “Effects of gum arabic (Acacia senegal) on renal function in diabetic mice,” Kidney and Blood Pressure Research, vol. 35, no. 5, pp. 365–372, 2012.

[24] P. Fossati, L. Prencepi, and G. Berti, “Enzymic creatinine assay: a new colorimetric method based on hydrogen peroxide measurement,” Clinical Chemistry, vol. 29, no. 8, pp. 1494–1496, 1983.

[25] E. Soupenne, S. K. Larkin, and F. A. Kuypers, “Featured article: depletion of HDL1 high density lipoprotein and altered functionality of HDL2 in blood from sickle cell patients,” Experimental Biology and Medicine, vol. 242, no. 12, pp. 1244–1253, 2017.

[26] E. Soupenne, M. S. Borja, M. Borda, S. K. Larkin, and F. A. Kuypers, “Featured article: alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A1 functionality in human sickle blood,” Experimental Biology and Medicine, vol. 241, no. 17, pp. 1933–1942, 2016.

[27] S. K. Ballas, M. R. Kesen, M. F. Goldberg et al., “Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management,” The Scientific World Journal, vol. 2012, Article ID 949535, 2012.

[28] C. Hoppe, E. Jacob, L. Styles, F. Kuypers, S. Larkin, and E. Vichinsky, “Simvastatin reduces vaso-occlusive pain in sickle cell anemia: a pilot efficacy trial,” British Journal of Haematology, vol. 177, no. 4, pp. 620–629, 2017.

[29] C. Hoppe, F. Kuyppers, S. Larkin, W. Harag, E. Vichinsky, and L. Styles, “A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction,” British Journal of Haematology, vol. 153, no. 5, pp. 655–663, 2011.

[30] R. E. Mohamed, M. O. Gadour, and I. Adam, “The lowering effect of Gum Arabic on hyperlipidemia in Sudanese patients,” Frontiers in Physiology, vol. 6, p. 160, 2015.

[31] R. Babiker, K. Elmusharaf, M. B. Keogh, and A. M. Saeed, “Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial,” Lipids in Health and Disease, vol. 17, no. 1, p. 56, 2018.

[32] A. O. Babiker and L. A. Kaddam, “Risk factors of metabolic syndrome among adult Sudanese sickle cell anemia patients,” BMC Hematology, vol. 18, no. 1, Article no 18, 2018.

[33] M. Armogida, R. Nisticò, and N. B. Mercuri, “Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia,” British Journal of Pharmacology, vol. 166, no. 4, pp. 1211–1224, 2012.

[34] J. Titus, S. Char, M. Gupta, and N. Parekh, “Pro-oxidant and anti-oxidant status in patients of sickle cell anemia,” Indian Journal of Clinical Biochemistry, vol. 19, no. 2, pp. 168–172, 2004.

[35] A. Marques de Mattos, L. V. Marino, P. P. Ovidio, A. A. Jordão, C. C. Almeida, and P. G. Chiarello, “Protein oxidative stress and dyslipidemia in dialysis patients,” Therapeutic Apheresis and Dialysis, vol. 16, no. 1, pp. 68–74, 2012.

[36] G. Caimi, R. L. Presti, M. Montana et al., “Lipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 824756, 8 pages, 2014.

[37] E. Hopp, D. Noto, G. Caimi, and M. R. Averna, “A novel component of the metabolic syndrome: the oxidative stress,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 20, no. 1, pp. 72–77, 2010.

[38] W. Calame, A. R. Weseler, C. Viebke, C. Flynn, and A. D. Siemonsma, “Gum Arabic establishes prebiotic functionality in healthy human volunteers in a dose-dependent manner,” British Journal of Nutrition, vol. 100, no. 6, pp. 1269–1275, 2008.

[39] G. T. Macfarlane and S. Macfarlane, “Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics,” Journal of Clinical Gastroenterology, vol. 45, no. 3, pp. S120–S127, 2011.

[40] A. Everard, V. Lazarevic, M. Derrien et al., “Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice,” Diabetes, vol. 60, no. 11, pp. 2775–2786, 2011.

[41] B. D. Pachikian, A. Essaghir, J.-B. Demoulin et al., “Prebiotic approach alleviates hepatic steatosis: implication of fatty acid oxidative and cholesterol synthesis pathways,” Molecular Nutrition & Food Research, vol. 57, no. 2, pp. 347–359, 2013.